CSL Limited (CSLLY) Stock

About CSL Limited

CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international presence, with operations spanning major markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China, alongside other territories worldwide. Its business is primarily structured around two key divisions: CSL Behring and Seqirus. The CSL Behring segment specializes in plasma-derived and recombinant therapies, which are crucial for treating serious medical conditions including immunodeficiency, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments. This division also conducts extensive research into both plasma and non-plasma-based treatments and generates income through licensing agreements and royalties from its proprietary innovations. In contrast, the Seqirus segment is focused on manufacturing and supplying biotherapeutic products that are not derived from plasma, with a particular emphasis on the development of solutions related to influenza. CSL Limited, originally founded in 1916, has its corporate headquarters situated in Parkville, Australia.

CSL Limited is headquartered in AU.

CSL Limited (CSLLY) stock trades at $23.52 with a market capitalization of $91.08B. The stock is valued at a price-to-earnings (P/E) ratio of 31.36, price-to-book of 2.42, price-to-sales of 2.85. Over the past 52 weeks the stock has ranged between $16.01 and $44.78, and currently trades 47.5% below its 52-week high. It pays a dividend yielding 2.72%.

On profitability, CSL Limited generates a return on equity (ROE) of 7.56%, return on capital employed of 12.12%, an operating margin of 25.72%, a net profit margin of 9.17%.

In its most recent fiscal year, CSL Limited reported annual revenue of $15.4B, net profit of $3.0B, revenue has compounded at 11.1% a year over the last five years, profit at 15.6% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.67, a current ratio of 2.57, total assets of $39.4B, $2.2B in cash and equivalents.

CSLLY has an average daily trading volume of 463,225 shares, a beta of 0.08 (less volatile than the overall market).

Official website: www.csl.com